New England Journal of Medicine· 2015Q1

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Dung T. Le, Jennifer N. Uram, Hao Wang, Bjarne R. Bartlett et al.

9,492citations
Q1SCImago
2015year

Short summary

Pembrolizumab, an anti-PD-1 immune checkpoint inhibitor, achieved a 40% objective response rate and 78% 20-week progression-free survival in patients with mismatch repair-deficient (dMMR) metastatic colorectal cancer, compared to 0% and 11% in mismatch repair-proficient (pMMR) tumors.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Oncology

OncologyMedicine